Physiologically based pharmacokinetic model of lapatinib developed in mice and scaled to humans

Lapatinib Distribution in HER2 Overexpressing Experimental Brain Metastases of Breast Cancer

(2011) Kunal S. Taskar et al.   PHARMACEUTICAL RESEARCH

Comparison and evaluation of pharmacokinetics of PFOA and PFOS in the adult rat using a physiologically based pharmacokinetic model

(2011) Anne E. Loccisano et al.   REPRODUCTIVE TOXICOLOGY

Effects of ketoconazole and carbamazepine on lapatinib pharmacokinetics in healthy subjects

(2009) Deborah A. Smith et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

CYP2B6(c.516G→T) andCYP2A6(*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients

(2009) Awewura Kwara et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

A Phase I and Pharmacokinetic Study of Oral Lapatinib Administered Once or Twice Daily in Patients with Solid Malignancies

(2009) H. A. Burris et al.   CLINICAL CANCER RESEARCH

Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer

(2009) N. U. Lin et al.   CLINICAL CANCER RESEARCH

Evaluation of Lapatinib and Topotecan Combination Therapy: Tissue Culture, Murine Xenograft, and Phase I Clinical Trial Data

(2008) J. R. Molina et al.   CLINICAL CANCER RESEARCH

A Phase I and Pharmacokinetic Study of Lapatinib in Combination with Letrozole in Patients with Advanced Cancer

(2008) Q. S.C. Chu et al.   CLINICAL CANCER RESEARCH

An Unexpected Synergist Role of P-Glycoprotein and Breast Cancer Resistance Protein on the Central Nervous System Penetration of the Tyrosine Kinase Inhibitor Lapatinib (N- -6-[5-( methyl)-2-furyl]-4-quinazolinamine; GW572016)

(2008) J. W. Polli et al.   DRUG METABOLISM AND DISPOSITION

Phase I Dose-escalation and Pharmacokinetic Trial of Lapatinib (GW572016), a Selective Oral Dual Inhibitor of ErbB-1 and -2 Tyrosine Kinases, in Japanese Patients with Solid Tumors

(2008) K. Nakagawa et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Phase I and Pharmacokinetic Study of Lapatinib and Docetaxel in Patients With Advanced Cancer

(2008) Patricia M. LoRusso et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Dose Escalation and Pharmacokinetic Study of Lapatinib in Combination With Trastuzumab in Patients With Advanced ErbB2-Positive Breast Cancer

(2008) Anna Maria Storniolo et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of Lapatinib on the Outgrowth of Metastatic Breast Cancer Cells to the Brain

(2008) B. Gril et al.   JNCI-Journal of the National Cancer Institute